WilliamVWalshMD

Oncology • Worcester, MA

Associate Professor, Medicine, University Massachusetts Medical School

Join to view full profile

Dr. Walsh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Walsh's full profile

Already have an account?

Office
55 Lake Ave N
Department Of Hematology/Oncology
Worcester, MA 01655
Phone+1 508-334-3550

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1989 - 1992
National Capital Consortium (Walter Reed)Residency, Internal Medicine, 1985 - 1988
George Washington University School of Medicine and Health SciencesClass of 1985
Harvard CollegeB.A., Biochemistry and Molecular Biology , 1976 - 1980

Certifications & Licensure

MA State Medical License 1995 - 2026
CT State Medical License 1995 - 2012
MD State Medical License 1988 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2013 Nov 01
Terminated
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

2558 citations
A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
Michael B. Kastan, Qimin Zhan, Wafik S. El-Deiry, Tyler Jacks, William V. Walsh
Cell. 1992-11-13
12 citations
Coordination and optimization of FDG PET/CT and COVID-19 vaccination; Lessons learned in the early stages of mass vaccination.
Lacey J. McIntosh, Max P. Rosen, Kriti Mittal, Giles F. Whalen, Venu Bathini
Cancer Treatment Reviews. 2021-05-11
1487 citations
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Steven J. Kuerbitz, Beverly Plunkett, William V. Walsh, Michael B. Kastan
Proceedings of the National Academy of Sciences of the United States of America. 1992-08-15

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member